Cambridge Major Laboratories and AAIPharma Appoint CEO of Merged Company
Cambridge Major Laboratories and AAIPharma Services appoints Patrick D. Walsh as CEO of merged company.
Cambridge Major Laboratories, a provider of pharmaceutical API development and manufacturing, and the CDMO/CMO AAIPharma Services have appointed Patrick D. Walsh as the CEO of the merged company. In October 2013, Cambridge and AAIPharma announced their intent to merge. The combined company forms a supplier of integrated chemistry manufacturing and control (CMC) services, including process chemistry, solid state chemistry, API manufacturing, formulation development, analytical development and testing services, clinical and commercial finished dosage-form manufacturing (oral solid and sterile), and packaging and stability services.
Source: AAIPharma Service
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
